The Etanercept Curative Effect Observation On Treatment Of Ankylosing Spondylitis And Analysis Of Follow-up Treatment

objective:Observation of etanercept in ankylosing spondylitis (AS) preliminary clinical efficacy; to explore the timing and method of AS patients in accordance with etanercept for some time after the reduction; comparison of etanercept, the use of different abiotic the preparations for the follow-up treatment efficacy, to explore the follow-up treatment programs AS etanercep.method:February2010to February2012in our hospital during the80cases of etanercept treatment in patients with ankylosing spondylitis, record the patient’s age, gender, disease duration, erythrocyte sedimentation rate, C-reactive protein, liver and kidney function, and HLA-B27in; sacroiliac joint X-ray or CT findings, and previous DMARD usage; Basis recommended in patients with AS Assessment Working Group (ASAS) response criteria evaluation. The four areas evaluated from the average of two VAS parameters of morning stiffness in spinal inflammation score (BASDAI), spinal pain, the VAS, the patient overall evaluation of the VAS and the Bath Ankylosing Spondylitis Functional Index (BASFI).8and12weeks after the statistical treatment evaluation, records of the number of cases and percentage of ASAS20then The reach ASAS20patients were randomly divided into three groups, The first group were given thalidomide100mg, qn, the second group given sulfasalazine1.0g bid for the third group was treated with thalidomide treatment of sulfasalazine, respectively, at16,20and24weeks, statistical evaluation achieve the number of cases and percentage of ASAS20. Other evaluation also includes the BASDAI composite index and the independent parameters, erythrocyte sedimentation rate, C-reactive protein, the relapse rate of patients in each observation period statistics.Results: 1) Played a better clinical effect of etanercept treatment of ankylosing spondylitis patients, the use of etanercept to four weeks, patients in BASDAI, spinal pain, the VAS, the patient overall evaluation of the VAS and BASFI improved significantly compared with that before treatment significant difference, with statistical significance (P<0.05); treatment to four weeks, the ESR, CRP levels decreased significantly compared with that before treatment a significant difference, with statistical significance (P<0.05).8and12weeks to reach ASAS20the number of cases and percentage significantly higher than the first4weeks (P<0.05);8and12weeks to reach the number of cases and percentage of ASAS50significantly higher than the first4weeks (P<0.05).2) In the follow-up treatment, oral thalidomide for treatment of sulfasalazine is superior to a separate oral thalidomide or sulfasalazine,20,24weeks, the joint treatment of patients with BASDAI, spinal pain VAS, patient as a whole evaluation of the VAS, BASFI, the ESR, CRP, indicators significantly better than the first group and second group (P<0.05).24weeks after treatment, combination therapy patients, case number and percentage of ASAS20significantly higher than the first group and second group (P<0.05); and the relapse rate was slightly lower than the thalidomide group (P<0.05). much lower than the sulfasalazine group (P<0.01).discussion:According to etanercept treatment of ankylosing spondylitis with rapid onset of clinical effect can quickly relieve the clinical symptoms, has played a very important role for short-term and long-term treatment of AS. In the follow-up treatment of ankylosing spondylitis, thalidomide clinical effects of sulfasalazine treatment is better than a single thalidomide or sulfasalazine treatment, but also has a good safety and tolerability, can alleviate the economic pressures brought about by long-term use of etanercept, and worthy of promotion and application. However, thalidomide plus sulfasalazine treatment of long-term efficacy and long-term security is worth further study.